[Retracted] Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms

<div>Molecular subtypes are associated with distinct clinical outcomes. (a) Overall survival analysis of R-CHOP-treated DLBCL patients in subtypes I and II. (b) Progression-free survival analysis of patients in subtypes I and II. Red represents subtype I, and blue indicates subtype II.</div>

BioMed Research International

fig2

Figure 2

Figure 2: [Retracted] Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms 

Figure 2 | [Retracted] Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms 